fda warning letters glp-1 compounders september 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading FDA cracks down on 'misleading'

95% CI, 0.13 to 0.86

[DOI] [PMC free article] [PubMed] [Google Scholar] 43.Pandey S., Mangmool S., Parichatikanond W

Clinical trials show that individuals who have been treated can expect an average of 24 percent of their total body weight loss within about 48 weeks

Warnings Tirzepatide carries a Boxed Warning for the risk of possible thyroid tumors

The group, Public Employees for Environmental Responsibility (PEER), obtained pesticide testing data from the EPA through a Freedom of Information Act (FOIA) request

These agents include: Liraglutide (Victoza, Saxenda) once-daily injection Semaglutide (Ozempic, Wegovy) once-weekly Tirzepatide (Mounjaro) a dual GLP-1/GIP agonist From Glycaemic Control to Weight Regulation GLP-1RAs were initially licensed to lower HbA1c in people with Type 2 diabetes, offering an alternative to sulfonylureas and insulin